<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03274804</url>
  </required_header>
  <id_info>
    <org_study_id>PICCASSO</org_study_id>
    <nct_id>NCT03274804</nct_id>
  </id_info>
  <brief_title>Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC</brief_title>
  <acronym>PICCASSO</acronym>
  <official_title>A Phase I Trial of Combined PD-1 Inhibition (Pembrolizumab) and CCR5 Inhibition (Maraviroc) for the Treatment of Refractory Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a monocentric, single arm, prospective, open-label trial of a combination treatment&#xD;
      consisting of pembrolizumab and maraviroc in previously treated subjects who have refractory&#xD;
      microsatellite stable (MSS) metastatic colorectal cancer (mCRC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle&#xD;
      (d1, qd22) together with maraviroc administered perorally on day 1 to 21 of each cycle&#xD;
      (d1-21; qd22).&#xD;
&#xD;
      Treatment with pembrolizumab / maraviroc combination will continue until progressive disease&#xD;
      (PD), unacceptable adverse events (AEs), intercurrent illness that prevents further&#xD;
      administration of treatment, investigator's decision to withdraw the subject, subject&#xD;
      withdraws consent, pregnancy of the subject, noncompliance with trial treatment or procedure&#xD;
      requirements, administrative reasons requiring cessation of treatment, or completion of&#xD;
      treatment per protocol.&#xD;
&#xD;
      Subjects with a treatment response or stable disease after completion of the first treatment&#xD;
      phase of eight cycles (core treatment period) will be offered, at the discretion of the&#xD;
      investigator, participation in a maintenance phase consisting of up to 24 additional&#xD;
      treatment cycles of pembrolizumab monotherapy (total treatment duration up to 24 months).&#xD;
&#xD;
      Subjects who discontinue for reasons other than PD will have post-treatment follow-up for&#xD;
      disease status until PD, initiating a non-study cancer treatment, withdrawing consent, or&#xD;
      becoming lost to follow-up. All subjects will be followed for overall survival (OS) until&#xD;
      death, withdrawal of consent, loss to follow-up, or the end of the study.&#xD;
&#xD;
      After the end of treatment, each subject will be followed for 30 days for AE monitoring.&#xD;
      Serious adverse events (SAEs) and AEs of special interest (AESIs) will be collected for 90&#xD;
      days after the end of treatment or for 30 days after the end of treatment if the subject&#xD;
      initiates new anticancer therapy, whichever is earlier.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility Rate of a Combined Therapy</measure>
    <time_frame>After core treatment period of 8 cycles (each cycle is 21 days)</time_frame>
    <description>Defined as the rate of patients receiving the protocol treatment according to the planned schedule without occurrence of at least one of the following events:&#xD;
Study treatment-related Grade ≥ 3 immune-related abnormalities; Study treatment-related Grade ≥ 4 AEs of any aetiology; Any toxic event leading to the premature withdrawal of protocol treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Toxicity of a Combined Therapy Based on Subjects Who Experienced Toxicities</measure>
    <time_frame>After core treatment period of 8 cycles (each cycle is 21 days)</time_frame>
    <description>The primary safety analysis will be based on subjects who experienced toxicities as defined by the current National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, v4.0; Section 11.2). The attribution to drug, time-of-onset, duration of the event, its resolution, and any concomitant medications administered will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint: Disease Control Rate</measure>
    <time_frame>through study completion (20 months)</time_frame>
    <description>Determine DCR defined as percentage of patients displaying CR/PR or SD as best response according to the RECIST criteria version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint: Objective Response Rate</measure>
    <time_frame>through study completion (20 months)</time_frame>
    <description>ORR and immune related (ir) ORR (irORR) will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint: Progression-free Survival</measure>
    <time_frame>through study completion (20 months)</time_frame>
    <description>Individual PFS will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>through study completion (20 months)</time_frame>
    <description>Individual OS will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Research to Assess the Immune Response in Whole Blood and Tumor Tissue as Well as the Identification of Biomarkers That Correlate With Clinical Response and/or Clinical Outcome</measure>
    <time_frame>through study completion (20 months)</time_frame>
    <description>Biomarker research related secondary endpoints are to assess the immune response in whole blood and tumor tissue as well as the identification of biomarkers that correlate with clinical response and/or clinical outcome.&#xD;
Therefore, blood-based biomarkers (e.g. changes in the cytokine profile) and tissue-based biomarkers in the biopsies of a metastatic lesion (e.g. T-cell infiltration, cytokines, tumor cell apoptosis) will be analyzed.&#xD;
Blood and tissue based changes in the immune response will be correlated with clinical response patterns.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <condition>MSS</condition>
  <arm_group>
    <arm_group_label>Single arm, prospective, open-label trial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22) together with maraviroc administered perorally on day 1 to 21 of each cycle (d1-21; qd22).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22)</description>
    <arm_group_label>Single arm, prospective, open-label trial</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>Maraviroc will be administered perorally on day 1 to 21 of each cycle (d1-21; qd22)</description>
    <arm_group_label>Single arm, prospective, open-label trial</arm_group_label>
    <other_name>Celsentri</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed metastatic colorectal cancer. Microsatellite stability (MSS)&#xD;
             is confirmed by PCR or immunohistochemistry.&#xD;
&#xD;
          2. Patient failed standard therapy or is intolerable towards standard therapy which must&#xD;
             include a fluoropyrimidine, oxaliplatin, irinotecan, an antiangiogenic monoclonal&#xD;
             antibody (e.g. bevacizumab, aflibercept, ramucirumab), an EGFR inhibitor in case of&#xD;
             RAS/BRAF wildtype tumors and optional regorafenib or TAS 102&#xD;
&#xD;
          3. Measurable disease as per RECIST 1.1&#xD;
&#xD;
          4. Metastatic lesion accessible for repetitive biopsies and patient willing to provide&#xD;
             tissue from newly obtained biopsies. Patients without accessible lesions might be&#xD;
             enrolled after discussion with the principle investigator.&#xD;
&#xD;
          5. ECOG performance status 0 or 1&#xD;
&#xD;
          6. Adequate hematological, hepatic and renal function parameters:&#xD;
&#xD;
               -  Leucocytes&gt; 3.000/μl&#xD;
&#xD;
               -  Hemoglobin &gt;9 g/dl&#xD;
&#xD;
               -  Thrombocytes &gt; 100.000/μl&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or GFR ≥60 mL/min for&#xD;
                  subject with creatinine levels &gt; 1.5 x institutional ULN&#xD;
&#xD;
               -  Serum total bilirubin ≤ 1.5 x upper limit of normal or direct bilirubin ≤ ULN for&#xD;
                  subjects with total bilirubin levels &gt; 1.5 ULN&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 x upper limit of normal (or ≤ 5 x if liver metastases are&#xD;
                  present)&#xD;
&#xD;
               -  Albumin ≥ 2.5 mg/dL&#xD;
&#xD;
          7. Adequate coagulation functions as defined by International Normalized Ratio (INR)&#xD;
             ≤1.5, and a partial thromboplastin time (PTT) ≤ 5 seconds above the ULN (unless&#xD;
             receiving anticoagulation therapy). Patients receiving warfarin/ phenprocoumon must be&#xD;
             switched to low molecular weight heparin and have achieved stable coagulation profile.&#xD;
&#xD;
          8. Female and male patients' ≥ 18 years. Patients in reproductive age must be willing to&#xD;
             use adequate contraception during the study and 4 months after the end of the study&#xD;
             (appropriate contraception is defined as surgical sterilization (e.g., bilateral tubal&#xD;
             ligation, vasectomy), hormonal contraception (implantable, patch, oral), and&#xD;
             doublebarrier methods (any double combination of: IUD, male or female condom with&#xD;
             spermicidal gel, diaphragm, sponge, cervical cap)). Abstinence (relative to&#xD;
             heterosexual activity) can be used as the sole method of contraception if it is&#xD;
             consistently employed as the subject's preferred and usual lifestyle and if considered&#xD;
             acceptable by local regulatory agencies and ERCs/IRBs. Periodic abstinence (e.g.,&#xD;
             calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are&#xD;
             not acceptable methods of contraception. Female patients with childbearing potential&#xD;
             need to have a negative pregnancy test within 7 days before study start.&#xD;
&#xD;
          9. Patient able and willing to provide written informed consent and to comply with the&#xD;
             study protocol and with the planned surgical procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to understand the aims of the study and/or protocol procedures&#xD;
&#xD;
          2. Hypersensitivity towards pembrolizumab, maraviroc, or any ingredients of the&#xD;
             formulations administered&#xD;
&#xD;
          3. History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies&#xD;
&#xD;
          4. Any other concurrent antineoplastic treatment including irradiation (local radiation&#xD;
             of single non-target lesions for palliation only allowed)&#xD;
&#xD;
          5. Active autoimmune disease requiring immunosuppressive therapy&#xD;
&#xD;
          6. Any condition requiring continuous systemic treatment with either corticosteroids (&gt;10&#xD;
             mg daily prednisone equivalents) or other immunosuppressive medications within 2 weeks&#xD;
             prior to first dose of study treatment. Inhaled or topical steroids and physiological&#xD;
             replacement doses of up to 10 mg daily prednisone equivalent are permitted in the&#xD;
             absence of active autoimmune disease.&#xD;
&#xD;
          7. Secondary malignant disease during the last 5 years (exceptions include basal cell&#xD;
             carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer&#xD;
             that has undergone potentially curative therapy).&#xD;
&#xD;
          8. Clinical relevant comorbidity also including significant psychiatric disease&#xD;
&#xD;
          9. Clinically significant active coronary heart disease, cardiomyopathy or congestive&#xD;
             heart failure, NYHA III-IV&#xD;
&#xD;
         10. Cardiocirculatory insufficiency with hypotension (systolic blood pressure &lt;100 mmHg)&#xD;
&#xD;
         11. Cirrhosis of the liver (Child &gt; Grade A), pronounced alcohol abuse with anticipated&#xD;
             detoxification, severe pulmonary infection with considerable reduction of pulmonary&#xD;
             function&#xD;
&#xD;
         12. Prior allogeneic bone marrow transplantation&#xD;
&#xD;
         13. Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 therapeutic antibody&#xD;
&#xD;
         14. Administration of a live, attenuated vaccine within four weeks prior to start of&#xD;
             maintenance treatment or anticipation that such a live attenuated vaccine will be&#xD;
             required during the remainder of the study Note: Seasonal influenza vaccines for&#xD;
             injection are generally inactivated flu vaccines and are allowed; however intranasal&#xD;
             influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not&#xD;
             allowed.&#xD;
&#xD;
         15. Chronic intake of drugs that lead to known interference with Maraviroc metabolism&#xD;
             through strong Cytochrome P450 3A4 (CYP3A4) interaction: e.g. Rifampicin, Rifabutin,&#xD;
             Clarithromycin, Telithromycin, Ketoconazole, Itraconazole, Fluconazole, Hypericum&#xD;
             perforatum (St. John's Worth /Johanniskraut) or any strong CYP3A4 inducing or&#xD;
             inhibiting drug (See Section 5.5.2)&#xD;
&#xD;
         16. Positive test for human immunodeficiency virus (HIV) or HIV infection&#xD;
&#xD;
         17. Active hepatitis B (defined as having a positive hepatitis B surface antigen [HBsAg]&#xD;
             test) or hepatitis C. Note: Patients with past hepatitis B virus (HBV) infection or&#xD;
             resolved HBV infection (defined as having a negative HBsAg test and a positive&#xD;
             antibody to hepatitis B core antigen antibody test) are eligible.&#xD;
&#xD;
         18. Active or latent tuberculosis&#xD;
&#xD;
         19. Clinically active brain metastases, defined as untreated symptomatic, or requiring&#xD;
             therapy with steroids or anticonvulsants to control associated symptoms.&#xD;
&#xD;
             Subjects with treated brain metastases that are no longer symptomatic and require no&#xD;
             treatment with steroids may be included in the study if they have recovered from the&#xD;
             acute toxic effect of radiotherapy and have no evidence of disease progression on&#xD;
             imaging studies (MRI/CT scan).&#xD;
&#xD;
         20. On-treatment participation in another clinical study in the period 30 days prior to&#xD;
             start of study treatment and during the study&#xD;
&#xD;
         21. Patients in a closed institution according to an authority or court decision (AMG §&#xD;
             40, Abs. 1 No. 4)&#xD;
&#xD;
         22. Pregnancy or lactation&#xD;
&#xD;
         23. Known history of, or any evidence of active, non-infectious pneumonitis or&#xD;
             interstitial lung disease.&#xD;
&#xD;
         24. Active infection requiring systemic therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Jäger, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCT, Med Oncology, University Hospital Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Center for Tumor Diseases, University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 14, 2017</study_first_submitted>
  <study_first_submitted_qc>September 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2017</study_first_posted>
  <results_first_submitted>February 1, 2021</results_first_submitted>
  <results_first_submitted_qc>March 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 22, 2021</results_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Dirk Jäger</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT03274804/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Arm, Prospective, Open-label Trial</title>
          <description>Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22) together with maraviroc administered perorally on day 1 to 21 of each cycle (d1-21; qd22).&#xD;
Pembrolizumab: Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22)&#xD;
Maraviroc: Maraviroc will be administered perorally on day 1 to 21 of each cycle (d1-21; qd22)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The required parameters as defined in the inclusion and exclusion criteria are met by all patients.</population>
      <group_list>
        <group group_id="B1">
          <title>Study Treatment Arm</title>
          <description>All enrolled subjects received pembrolizumab 200 mg IV on day one every three weeks (d1, qd22; Q3W) plus maraviroc 2 x 300 mg p.o. daily as combination therapy in an unblinded fashion.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="8.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Feasibility Rate of a Combined Therapy</title>
        <description>Defined as the rate of patients receiving the protocol treatment according to the planned schedule without occurrence of at least one of the following events:&#xD;
Study treatment-related Grade ≥ 3 immune-related abnormalities; Study treatment-related Grade ≥ 4 AEs of any aetiology; Any toxic event leading to the premature withdrawal of protocol treatment</description>
        <time_frame>After core treatment period of 8 cycles (each cycle is 21 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm, Prospective, Open-label Trial</title>
            <description>All enrolled subjects received pembrolizumab 200 mg IV on day one every three weeks (d1, qd22; Q3W) plus maraviroc 2 x 300 mg p.o. daily as combination therapy in an unblinded fashion.</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility Rate of a Combined Therapy</title>
          <description>Defined as the rate of patients receiving the protocol treatment according to the planned schedule without occurrence of at least one of the following events:&#xD;
Study treatment-related Grade ≥ 3 immune-related abnormalities; Study treatment-related Grade ≥ 4 AEs of any aetiology; Any toxic event leading to the premature withdrawal of protocol treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Toxicity of a Combined Therapy Based on Subjects Who Experienced Toxicities</title>
        <description>The primary safety analysis will be based on subjects who experienced toxicities as defined by the current National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, v4.0; Section 11.2). The attribution to drug, time-of-onset, duration of the event, its resolution, and any concomitant medications administered will be recorded.</description>
        <time_frame>After core treatment period of 8 cycles (each cycle is 21 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Treatment Arm</title>
            <description>All enrolled subjects received pembrolizumab 200 mg IV on day one every three weeks (d1, qd22; Q3W) plus maraviroc 2 x 300 mg p.o. daily as combination therapy in an unblinded fashion.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Toxicity of a Combined Therapy Based on Subjects Who Experienced Toxicities</title>
          <description>The primary safety analysis will be based on subjects who experienced toxicities as defined by the current National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, v4.0; Section 11.2). The attribution to drug, time-of-onset, duration of the event, its resolution, and any concomitant medications administered will be recorded.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Endpoint: Disease Control Rate</title>
        <description>Determine DCR defined as percentage of patients displaying CR/PR or SD as best response according to the RECIST criteria version 1.1.</description>
        <time_frame>through study completion (20 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Treatment Arm</title>
            <description>All enrolled subjects received pembrolizumab 200 mg IV on day one every three weeks (d1, qd22; Q3W) plus maraviroc 2 x 300 mg p.o. daily as combination therapy in an unblinded fashion.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Endpoint: Disease Control Rate</title>
          <description>Determine DCR defined as percentage of patients displaying CR/PR or SD as best response according to the RECIST criteria version 1.1.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Endpoint: Objective Response Rate</title>
        <description>ORR and immune related (ir) ORR (irORR) will be analyzed.</description>
        <time_frame>through study completion (20 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm, Prospective, Open-label Trial</title>
            <description>All enrolled subjects received pembrolizumab 200 mg IV on day one every three weeks (d1, qd22; Q3W) plus maraviroc 2 x 300 mg p.o. daily as combination therapy in an unblinded fashion.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Endpoint: Objective Response Rate</title>
          <description>ORR and immune related (ir) ORR (irORR) will be analyzed.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Endpoint: Progression-free Survival</title>
        <description>Individual PFS will be analyzed.</description>
        <time_frame>through study completion (20 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Treatment Arm</title>
            <description>All enrolled subjects received pembrolizumab 200 mg IV on day one every three weeks (d1, qd22; Q3W) plus maraviroc 2 x 300 mg p.o. daily as combination therapy in an unblinded fashion.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Endpoint: Progression-free Survival</title>
          <description>Individual PFS will be analyzed.</description>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Individual OS will be analyzed.</description>
        <time_frame>through study completion (20 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Treatment Arm</title>
            <description>All enrolled subjects received pembrolizumab 200 mg IV on day one every three weeks (d1, qd22; Q3W) plus maraviroc 2 x 300 mg p.o. daily as combination therapy in an unblinded fashion.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Individual OS will be analyzed.</description>
          <units>Time until event, month</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="6.00" upper_limit="20.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarker Research to Assess the Immune Response in Whole Blood and Tumor Tissue as Well as the Identification of Biomarkers That Correlate With Clinical Response and/or Clinical Outcome</title>
        <description>Biomarker research related secondary endpoints are to assess the immune response in whole blood and tumor tissue as well as the identification of biomarkers that correlate with clinical response and/or clinical outcome.&#xD;
Therefore, blood-based biomarkers (e.g. changes in the cytokine profile) and tissue-based biomarkers in the biopsies of a metastatic lesion (e.g. T-cell infiltration, cytokines, tumor cell apoptosis) will be analyzed.&#xD;
Blood and tissue based changes in the immune response will be correlated with clinical response patterns.</description>
        <time_frame>through study completion (20 months)</time_frame>
        <posting_date>07/2021</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of treatment allocation through 30 days following discontinuation of treatment, up to 20 months, all adverse events must be reported by the investigator.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Treatment Arm</title>
          <description>The primary safety analysis will be based on subjects who experienced toxicities as defined by the current National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, v4.0; Section 11.2). The attribution to drug, time-of-onset, duration of the event, its resolution, and any concomitant medications administered will be recorded.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other</sub_title>
                <description>unknown origin</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hemorrhoidal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Salivary gland infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Georg Martin Haag</name_or_title>
      <organization>Universitätsklinikum Heidelberg, NCT</organization>
      <phone>+49 (0) 6221 56 3 ext 7630</phone>
      <email>GeorgMartin.Haag@med.uni-heidelberg.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

